Figure 4. Self-sufficient LSR-based control of pramlintide expression in diet-induced obese mice.

(a–d) Mice fed for 14 weeks with standard LF (5 kcal% fat), MF (10 kcal% fat) and HF (60 kcal% fat) diets were implanted with pKR135/pKR146-transgenic HT-1080 (2 × 10⁶ cells per mouse) (LSR-Pramlintide) or the isogenic pKR135/pMG10-transgenic HT-1080 (2 × 10⁶ cells per mouse) (Control). Seventy-two hours after implantation, blood pramlintide levels (a) and blood fat levels represented by serum cholesterol and phospholipid concentrations (b), as well as change in food intake (c) and weight loss (d) were profiled. (e) Illustrations showing implanted microencapsulated circuit-transgenic HT-1080 (pKR135/pKR146) of two different dissected mice. Data are mean±s.e.m., statistics by two-tailed Student’s t-test; n=8 mice per group. *P<0.05, **P<0.005, ***P<0.0001 versus LF mice.